Beyond PD-L1, co-mutation set has yet to be prospectively validated to select candidates for concurrent BRAF–MEK inhibition with PD-1 blockade therapy in NSCLC. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.